Granulocytes
Stockholm, Sweden, June 13–16, 2013 Granulocytes P1024 LIPEGFILGRASTIM–A LONG-ACTING, ONCE-PER-CYCLE, GLYCOPEGY - LATED RECOMBINANT HUMAN FILGRASTIM CREATED WITH SITE-SPE - P1022 CIFIC GLYCOPEGYLATION TECHNOLOGY C Scheckermann 1,* , K Schmidt 1, A Abdolzade-Bavil 1, H Allgaier 2, U Mueller 3, IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN W Shen 4, P Liu 5 BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRAT - 1BioGeneriX GmbH, 2Merckle Biotec GmbH, 3Teva GmbH, Ulm, Germany, ED ANALYSIS FROM PHASE II AND III STUDIES 4Teva Pharmaceuticals, West Chester, 5Teva Pharmaceuticals, Washington A Abdolzade-Bavil 1,* , L Zou 2, C Sadhu 3, A Buchner 4, P Liu 3 DC, United States 1BioGeneriX GmbH, Ulm, Germany, 2Teva Pharmaceuticals, Rockville, 3Teva Biopharmaceuticals, Washington DC, United States, 4Teva ratiopharm, Ulm, Background: Lipegfilgrastim is a once-per-cycle, fixed-dose glycoPEGylated Germany granulocyte-colony stimulating factor (G-CSF) under development for the preven - tion of severe neutropenia in cancer patients receiving chemotherapy (CTx). Tra - Background: Lipegfilgrastim is a novel, long-acting, fixed-dose, glycoPEGy - ditional PEGylation of biologic molecules has been used successfully for more lated recombinant granulocyte-colony stimulating factor (rG-CSF) under review than 10 years to extend the half-life in the body, requiring less frequent dosing for neutropenia prevention in patients receiving myelosuppressive chemother - and allowing for the administration of G-CSF once per CTx cycle, making treat - apy (CTx) for cancer. Like any biological product, lipegfilgrastim could poten - ment potentially less expensive and enhancing patient compliance and safety. tially elicit an anti-drug antibody (ADA) response, which could cause adverse However, the traditional PEGylation use of chemical conjugation through reac - events (AEs) or lack of efficacy.
[Show full text]